Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been given an average rating of “Moderate Buy” by the twenty ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $272.7368.

JAZZ has been the subject of several recent research reports. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a report on Tuesday. Bank of America lifted their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Morgan Stanley boosted their price objective on Jazz Pharmaceuticals from $245.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday. Leerink Partners increased their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Finally, Weiss Ratings raised shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a report on Tuesday.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz’s quarterly revenue reached $1.21 billion, beating consensus expectations of $1.11 billion and increasing 15.5% year over year. Management also raised its 2026 revenue outlook to $4.60 billion-$4.75 billion, supported by its neuroscience and oncology businesses. What Does Jazz Pharmaceuticals Raised Guidance Mean
• Positive Sentiment: The company’s oxybate franchise, including Xywav, continues to post double-digit growth despite generic Xyrem competition, helping support confidence in the upgraded outlook.
• Positive Sentiment: Analyst sentiment has strengthened. Wells Fargo raised its price target to $300 and maintained an overweight rating, while Morgan Stanley lifted its target to $280. Other firms, including JPMorgan, Needham and Bank of America, also maintain bullish ratings or targets above the recent trading range. Wells Fargo Gives Jazz Pharmaceuticals a Buy
• Positive Sentiment: Ziihera, or zanidatamab, remains a potential catalyst, with an FDA decision expected August 25 for first-line gastroesophageal adenocarcinoma. Approval could expand Jazz’s oncology revenue base.
• Positive Sentiment: Recent coverage describes JAZZ as a strong long-term momentum and value candidate, reflecting its improving earnings outlook and stock performance near its 52-week high. Why Jazz Pharmaceuticals Is a Top Momentum Stock
• Neutral Sentiment: Adjusted earnings per share were $5.71, below the $6.18 consensus estimate. The revenue beat and higher guidance offset the earnings miss, but margins and future profitability remain important risks.
• Negative Sentiment: Jazz plans to seek FDA withdrawal of the second-line lurbinectedin, marketed as Zepzelca, indication for small-cell lung cancer. The move removes a potential regulatory catalyst and underscores pressure on the product’s development prospects. Jazz Seeks FDA Withdrawal of Lurbinectedin Indication
• Negative Sentiment: Director Bruce Cozadd sold 6,000 shares for approximately $1.52 million. The transaction occurred under a pre-arranged Rule 10b5-1 plan and reduced his position by only 1.64%, making it a limited negative signal. Jazz Pharmaceuticals Director Share Sale

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $256.56 on Friday. Jazz Pharmaceuticals has a 12-month low of $109.87 and a 12-month high of $265.05. The firm has a market capitalization of $16.66 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company has a current ratio of 1.78, a quick ratio of 1.85 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average of $241.29 and a 200 day moving average of $209.52.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company’s revenue was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($8.25) EPS. On average, research analysts anticipate that Jazz Pharmaceuticals will post 21.62 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. This represents a 1.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 19,098 shares of company stock worth $4,649,786. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. USA Financial Formulas bought a new position in Jazz Pharmaceuticals in the 1st quarter worth approximately $25,000. Arista Wealth Management LLC purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $61,000. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 18.8% during the second quarter. GAMMA Investing LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $339,000 after buying an additional 223 shares during the last quarter. Finally, Harbor Investment Advisory LLC lifted its holdings in shares of Jazz Pharmaceuticals by 349.2% in the second quarter. Harbor Investment Advisory LLC now owns 292 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 227 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.